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Abstract Chondroitin sulfate (CS) is the most abundant
glycosaminoglycan (GAG) in the central nervous system
(CNS) matrix. Its sulfation and epimerization patterns
give rise to different forms of CS, which enables it to
interact specifically and with a significant affinity with
various signalling molecules in the matrix including
growth factors, receptors and guidance molecules.
These interactions control numerous biological and path-
ological processes, during development and in adulthood.
In this review, we describe the specific interactions of
different families of proteins involved in various physio-
logical and cognitive mechanisms with CSs in CNS ma-
trix. A better understanding of these interactions could
promote a development of inhibitors to treat neurodegen-
erative diseases.
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Introduction
Chondroitin sulfate (CS) is an important sulfated carbohydrate
belonging to glycosaminoglycan family (GAG). CS was first
obtained from cartilage by Fisher and Boedecker in 1861 and
was isolated in purer form by Krukenburg in 1884. Seven
years later, Schmiedeberg showed that it contains a
hexosamine and hexuronic acid but the presence of a
sulfuronic group was not mentioned at that time [1]. It was
until 1915, Levene and Forge finally resolved the complete
structure of CS [2–5]. CS is composed of a D-glucuronic acid
(GlcA) and N-acetylgalactosamine (GalNAc) [1, 6]. Sulfation
is one of the main modification on CSs. The sulfation is often
added on C-4 and/or C-6 of GalNAc and/or C-2 of GlcA [7].
The sulfation position results in different forms of CS: CS-A,
CS-C, CS-D, CS-E (Fig. 1). This sulfation pattern confers
different roles to CSs and allows selective interactions with
different molecules. Apart from sulfation, GlcA can be
epimerized into L-iduronic acid (idoA) resulting in CS-B,
which is also called dermatan sulfate (DS; Fig. 1).
Like most GAGs, CS is located in the extracellular matrix
(ECM), at the cell surface or associated to the plasma mem-
brane, in most animal tissues [8]. As such they appeared to be
strategically positioned to control various important processes
occurring at the cell-tissue interface. It is also found in the
intracellular granules of certain cells like mast cells [8–10].
Both in the ECM and at the cell surface, CS is linked to a core
protein to form chondroitin sulfate proteoglycan (CSPG).
Localization of CSPGs in ECM make them more accessible
for different molecules involving in different mechanisms [11].
The expression of CS is tissue dependent and it is present at
a high level in the ECM in cartilage and central nervous sys-
tem (CNS). CS constitutes the most abundant GAG in the
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cartilage [12]. Many studies have reported the positive effect
of CS in treatment of osteoarthritis [13]. Indeed, CS inhibits
the apoptosis of chondrocytes, metalloproteases degradation
of cartilage, and activation of pro-inflammatory enzymes [14,
15]. CSPGs are also the major components of ECM in the
CNS. They are critical for the formation, development and
maintenance of brain morphology and function [16]. CSPGs
are highly upregulated in glial scar after CNS injury and they
inhibit axonal regeneration [16]. Recently, CSPGs have also
been shown to control memory retention in mouse model of
Alzheimer’s disease. Enzymatic removal of CSPGs en-
hances memory retention via enhanced plasticity, which
would be useful in improving condition such as neurode-
generation [17, 18].
CS composition is also cell-type dependent and changes at
different development stages. In nervous system, CS in the
ECM changes during ontogenesis. While CS-C is the most
expressed CS during embryogenesis, CS-A is the most abun-
dant in adulthood [19, 20]. Apart from biochemical evidence
using high performance liquid chromatography, these devel-
opmental changes in CSs are also confirmed using immuno-
logical techniques. Monoclonal antibodies are developed to
specifically recognise different isoforms of CS chain. This
tool provides the possibility of mapping the CS distribution
during ontogenesis [21]. Furthermore, the spatio-temporal ex-
pression of CSs in brain ECM has been investigated. It has
been shown that brain CSs exhibit structural diversity and
developmental regulation, which suggests that CSs are impli-
cated in diverse functions [22, 23].
The aim of this review is to provide an overview of all
reported CS-interacting proteins, with respect to brain func-
tion, how they are involved in the maintenance of the ECM
structure and their potential functional role. We focus on the
interaction of proteins with various CS sulfation pattern and
how these promote their signalling to accomplish their func-
tion including growth, differentiation, guidance and plasticity
within the CNS.
Organization of the CSPG network in the CNS
CSPG is the major component of ECM in the CNS
representing as much as ~20% of its total volume [24].
While the ratio of total CS vs heparan sulfate (HS) in the
CNS is 9:1, this ratio decreases to 7:3 in the perineuronal net
(PNN) matrix [25].
CSPG extraction from the brain ECM, using a sequential
method based on different buffers, revealed three distinct com-
partments: a diffuse matrix, a cell surface-associated matrix and
a condensed matrix, which contains different types and
amounts of CSPGs [25–27]. Almost all common CSPGs are
found in all three compartments, which bear different ECM
properties, but in different concentrations and with different
molecular characteristics. The use of physiological saline al-
lows the extraction of ECM molecules from the diffuse ECM.
Western blotting analysis showed that the diffuse matrix extract
contains all forms of neurocan, phosphacan (400 kDa) and
brevican (145 kDa) and aggrecan (>500 kDa). The cell
surface-associated matrix, which is released with detergent- or
high-salt buffer contains membrane associated CSPG – NG2
and also the other CSPGs. Finally the condensed matrix assem-
bly such as PNNs is extracted with 6 M urea buffer and con-
tains almost similar species of neurocan, brevican and
aggrecan, but without NG2. This compartment also contains
a large amount of versican [25, 27]. Other than core proteins,
the sulfation pattern of CS chains is also different in these
compartments. Disaccharide analysis has revealed that CS-A
is the major CS GAG in adult rat brain ECM and it is more
abundant in the diffuse matrix, whereas, the disulfated and/or
IdoA containing CSs including CS-B, CS-D and CS-E are
more abundant in the PNNs [25].
PNN is a highly organized ECM (Fig. 2) found mainly in
parvalbumin (PV) positive GABAergic interneurons in the
CNS although PNN is also observed in neurons without PV
expression [28–31]. This macromolecular assembly, in addi-
tion to CSPGs, is composed of hyaluronan (HA), link proteins
Fig. 1 Structure of disaccharide
units of chondroitin sulfate.
Chondroitin sulfate consists of
repeating disaccharide unit
composed of D-glucuronic acid
(GlcA) andN-acetylgalactosamine
(GalNAc). Each monosaccharide
may be sulfated on different resi-
dues. CS-A: carbon (C) 4 of the
GalNAc. CS-C: C6 of the
GalNAc. CS-D: C2 of the GlcA
and C6 of the GalNAc. CS-E: C4
and C6 of Gal-NAc. GlcA can be
epimerized into L-iduronic acid
(iA unit) resulting in CS-B
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and tenascin-R (Tn-R). HA is the backbone of PNN on which
CSPGs interact. It is synthetized by a transmembrane enzyme,
hyaluronan synthase (HAS) and is responsible for anchoring
PNN on the neuronal surface [32, 33]. Aggrecan is the key
CSPG for PNN formation in the cortex although its role can be
substituted by other CSPGs in other regions [33–35]. The
interaction of CSPGs and HA is stabilised by a family of
proteins called link protein, hyaluronan and proteoglycan-
binding link proteins (HAPLNs) [36]. This molecular interac-
tion is further stabilized by the trimeric Tn-R which can bind
up to three CSPGs [37]. Both HAPLN and Tn-R are crucial
for the stabilization and condensed nature of PNN [37, 38].
This unique molecular network looks optimally designed
to accomplish very specific functions. It has been proposed
that the immature PNNs act like a reservoir of molecules. It
attracts the neurotrophic factors responsible for the survival
and the growth of the neuronal cells [39]. Moreover, the ap-
pearance of the mature form of PNN coincides with the clo-
sure of the critical period, a period when experience-
dependant plasticity is consolidated [40]. It has been proposed
that PNN is important in stabilizing existing synapses and
inhibiting further or aberrant synapses formation [38, 40]. In
addition, PNNs are described as an ion exchanger in the brain.
The two major components of the PNN, HA chain and
CSPGs, are highly negatively charged, they can bind to the
cations in the ECM and regulate the ion mobility [41].
Proteins-GAGs interaction
GAGs interact with a large array of proteins to implement their
functions [42, 43]. This interaction is of great importance to
many physiological processes such as cell migration, growth,
differentiation, guidance and development [44, 45]. They are
also involved in pathological processes such as metastasis,
neurodegeneration and inflammation [46–49]. Most GAGs
are sulfated, including heparin (Hp), heparan sulfate (HS),
keratan sulfate (KS), CS, DS and it was initially assumed that
GAG-protein interaction is based on charge interaction.
Multiple consensus amino acid sequences on the various
GAG-binding proteins were later discovered on this basis
[50]. Cardin and Weintraub identified that heparin binds to
heparin-binding proteins through peptide sequences enriched
in basic residues such as X-B-B-X-B-X and X-B-B-B-X-X-B-
X where B is a basic residue and X is a hydropathic residue
[51]. A third heparin specific sequenceX-B-B-B-X-X-B-B-B-
X-X-B-B-X was later reported, first in Willebrand factor and
then in other proteins [52]. Further investigation has showed
the importance of secondary and tertiary structure or the spa-
tial distribution of basic residues. It has been shown, for ex-
ample, that a distance of about 20 Ǻ frequently separates two
basic amino acids in a number of heparin-binding peptides,
facing opposite directions of an alpha-helix [53]. More recent
work, however, also demonstrated that GAG binding sites can
be well identified by considering neutral hydrogen bond do-
nors, such as asparagine and glutamine, amino acids that im-
portantly contribute to the specificity of the interaction [54].
For CSs, they bind to CNS proteins containing a specific motif
rich in arginine and lysine, such as Otx2, which we shall
discuss more in the later section [55, 56].
The specificity and selectivity do not confine to protein
sequences, but are also dependent on the oligosaccharide se-
quence and the pattern of sulfation. Chemorepellent molecule
semaphorin 3A is found to interact with CS-E and B, but not
with CS-D even though these three CSs are all disulfated with
the same charge over mass ratio per disaccharide unit [56, 57].
Selective binding of neurotrophic factors like midkine and
BDNF to synthetic CS-E tetrasaccharide is observed and lead
to neurite outgrouth. Whereas the binding of these factors to
CS-R, a synthetic tetrasaccharide with the same number of
Fig. 2 Structure of PNNs. PNN
is composed mainly of CSPGs
from the family of lectican
(including aggrecan, versican,
bervican and neurocan),
hyaluronan (HA), link proteins
and tenascin-R (Tn-R). HA is the
backbone of PNN on which the
CSPGs lay. It is anchored by a
family of transmembrane en-
zymes, hyaluronan synthases
(HASs). CSPGs bind to HA via a
link protein. Tn-R is also involved
in the organisation of PNNs by
assembling of CSPGs at the C-
termini (Kwok et al. 2011)
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sulfate groups as CS-E but distributed differently, is very weak
and does not display a neuritogenic activity [58]. Also, differ-
ent types of HS binds to different types of fibroblast growth
factors (FGFs). For example, 2-O sulfate is required for the
binding of FGF-2, 6-O sulfate is required for the binding of
FGF-10 [59–62]. Recent evidence also shows that sulfation in
CS/DS affects the binding and activation of FGF-2 [63–65].
These findings suggest the importance of sulfation pattern of
GAGs in the specific binding to various proteins. Since HS is
the most abundant GAG in the extracellular environment of
many tissues, binding to HS/Hp is more documented than
those to CS and KS. Most of interactions proteins-CSs has
been characterized in the CNS.
Interactions of CSs with different families
of molecules in the CNS ECM
During development, immature neurons elongate their axons
through a complex tissue structure to reach their appropriate
synaptic partners located millimetres or even centimetres
away. Diverse cellular and molecular mechanisms are adopted
by embryos to guide the axons to their targets [66]. ECM
molecules play a crucial role during this process through the
involvement of either the ECM molecules or ECM-binding
molecules [67]. CSs interact and cooperate with extracellular
signalling proteins and receptors to modulate the axonal out-
growth. Removal of CSs by injection of chondroitinase ABC
(ChABC) results in abnormal axonal outgrowth in zebrafish
and rat embryos [68, 69] and disruption of retinal axons in
mouse embryos [70]. Otherwise, CNS development and CNS
injury share certain neural mechanisms including neural out-
growth, guidance and plasticity. Indeed, after CNS injury, the
same molecules involved in development are up-regulated
again, including CSPGs [71]. They form a chemical barrier,
which inhibits axonal projection and regeneration [72].
Enzymatic removal of CSs using ChABC promotes functional
recovery after spinal cord injury (SCI) in adult rats [73, 74].
ECM in the CNS is a rich source of signalling molecules
involved in different mechanisms of proliferation, differentia-
tion, survival and migration of neurons. Activities and interac-
tions of CSPGs with signalling molecules in ECM depend on
many parameters: the core protein, the attached CS chains, their
length, the degree and position of sulfates [75]. Composition of
CSPGs varies in stages of development and physiological state,
and this enables a large families of molecules, as described
below, to interact with CSPGs via CSs chains to accomplish
their functions (Fig. 3). The degree and position of sulfation on
the CS chains confer different specific binding sites to various
soluble factors in the ECM. Previous studies have reported an
upregulation of CS-E unit and also chondroitin 6-
sulfotransferase, an enzyme synthesising CS-C, after spinal
cord injury [76, 77]. In the PNNs, CS-E are responsible for
the binding of negative guidance molecule semaphorin 3A
(Sema3A) and Otx2 [55, 57, 78, 79]. Recently, there are also
studies describing the potential involvement of CS-C in epilep-
sy [80, 81]. These interactions lead to selective activation or
inhibition of various signalling pathways. Here, we describe a
families of proteins binding to CSs chain of CSPG to modulate
the axonal outgrowth and guidance.
i) Growth factors (GFs)
GFs are biomolecules which support proliferation, growth,
migration and differentiation [82–84]. In addition, they are
involved in regulating metabolism, tissue repair and maintain-
ing tissue homeostasis in adult organisms [85]. Some mem-
bers exist ubiquitously in all tissues but some are expressed in
a tissue-specific manner [86, 87]. GFs are usually secreted by
neighbouring cells or at nerve terminals into the ECM and act
locally due to their short life [88]. The secreted GFs bind to
specific receptors on the surface of target cells and induce
intracellular signalling pathway. Proteoglycans in the ECM
bind to the GFs, facilitate the access and presentation of GFs
to the receptor for subsequent signalling pathways [89].
During CNS development, many growth factors are shown
to interact with CS chains, which we shall discuss below.
Neurotrophic factors are the family of GFs that promote
survival, growth and differentiation of neuronal cells [90,
91]. Different neurotrophic factors, such as fibroblast growth
factor, has been postulated to interact with heparin to promote
the neurite outgrowth, hence their name Bheparin-binding
proteins^ [92]. Interaction of neurotrophic factors with
heparin/HS has attracted much attention similar to the in-
volvement of HS in development [93]. However, these last
decades more interest has been diverted to CSs notably in
the CNS [94]. Here we describe heparin-binding proteins
which interact with CSs in CNS.
Fibroblast growth factors (FGFs) are a large family of pro-
teins, which exert a pleiotropic effects in different tissues.
Basic fibroblast growth factor (bFGF) or FGF 2 is a multi-
functional growth factor including its effect on survival of
neurons and stimulate neurite extension [95]. It has been
shown that bFGF binding to HS-, Hp-, or HA-bound surfaces
stimulates neurite outgrowth from hippocampal neurons while
the binding to CS- or DS-surfaces does not lead to the same
observation [96]. On the other hand, Karumbaiah et al. has
reported the potential of CS-A hydrogel enriched in bFGF in
creating an endogenous niche for neural stem cells [97].
Surface plasmon resonance (SPR) analysis shows that CS-A
from bovine trachea binds with high affinity to bFGF, brain-
derived neurotrophic factor (BDNF) and interleukin 10 [97].
Screening of different GFs including FGF-2, −10, −16, −18
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and Hp-binding epidermal growth factor-like growth factor
(HB-EGF) against CS-E using filter binding assay, resonance
mirror biosensor IAsys and GAG microarrays showed that
these GFs bind to the CS-E from squid cartilage in a dose-
dependent manner [64, 65]. FGF-16, FGF-18, and HB-EGF
binds to CS-E (Kd ≈ 47.2, 8.9 and 16 nM, respectively) in a
comparable affinity to the binding to Hp (Kd ≈ 34.7, 10.8 and
4.7 nM, respectively), while the affinity of FGF-2 and FGF-10
toward CS-E was lower than Hp [64, 65]. Screening of these
GFs with oversulfated CS/DS hybrid chain purified from hag-
fish (CS-H) showed no binding by SPR, suggesting that the
binding of the GFs to CS-E is a specific interaction but not due
to non-specific charge interaction [98]. The binding of CS to
FGF2 is important for the formation of neural spheres, prolif-
eration and self-renewal of neural stem cells through the
FGF2/MAPK pathway [99]. Removal of CSs using ChABC
reduces neuronal proliferation and differentiation, and on the
contrary, it increases the proliferation of astrocytes [100].
Midkine and pleiotrophin are two basic heparin-binding pro-
teins localized in the radial glial fibres in embryonic brain,
along which neural stem cells migrate [101]. They mediate
neuronal cell adhesion and migration, and promote neurite out-
growth by interacting with cell surface heparin during develop-
ment [102, 103]. It has been shown that CS-C inhibits the
binding of pleiotrophin to its receptor 6B4 Proteoglycan/
Phosphacan, which is an extracellular variant of receptor-like
protein-tyrosine phosphatase (RPTP) ζ/RPTP β (this receptor
family will be discussed in the next section), in rat brain. The
binding of CS-C reduces pleiotrophin-induced neuronal migra-
tion along radial glial fibres. It has been postulated that CS and
a portion of RPTPζ/RPTPβ could constitute the binding site of
pleiotrophin [104, 105]. Similarly, Ueoka et al. have also
shown that the adhesion of embryonic cortical neurons to
midkine in culture is specifically inhibited by CS-E [106].
The interaction of midkine to CS-E is as strong as the binding
to Hp [106]. The specific and direct interaction between CS-E/
CS-H and midkine/pleiotrophin has also been shown by filter
binding assay, IAsys and SPR [64, 98, 107]. Midkine and
pleiotrophin are involved in neurodegenerative diseases such
as Alzheimer’s disease. Deposition ofmidkine and pleiotrophin
has been observed in the pathological senile plaque and/or
neurofibrillary tangles in Alzheimer’s brain [102, 108]. LDL
receptor-related protein (LRP) is a receptor of midkine and
Fig. 3 Interaction of CS glycan chains with different protein families in
CNS matrix. CSPGs inhibit the growth cone via the interaction of its CS
chain with 1) laminin and collagen and 2) bind its receptor protein
tyrosine kinase (RPTP). 3) The neuronal adhesion molecule NCAM
interacts with phosphacan (the extracellular part of RPTPζ) by its CS
chain and results in an inhibition of adhesion and neurite growth. 4)
CS, notably CS-E, acts as a binding partner of FGF to promote growth
and differentiation. 5) An interaction of semaphorin 5 A (Sema 5A) with
CS chain turns the attractive guidance protein into a repulsive cue.
Semaphorin 3A (Sema 3A) is a repulsive guidance protein found in
perineuronal nets and interacts specifically with CS-E motif. It exerts its
chemorepulsive effect by signalling via plexin-neuropilin receptors. CS
could be an additional constituent of sema 3A signalling complex
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pleiotrophin and it is genetically linked to Alzheimer’s disease
[102]. CS-Midkine/pleiotrophin interaction could be a potential
target to treat these diseases. Thus, further understanding of this
interaction should be performed. These findings suggest that
CSs could be a binding partner or co-receptor for neurotrophic
factors in the central nervous system.
ii) Receptors
Receptor protein tyrosine phosphatases (RPTPs) are a
family of receptor-enzymes that remove phosphate from tyro-
sine in a protein. RPTPs are commonly found on growth
cones [109] and are involved in the control of axon growth,
guidance, regeneration and plasticity during development as
well as after injury [110–112]. Indeed, a deficit of O-
mannosylated RPTP ζ contributes to congenital muscular dys-
trophies [113–115].
Members of class II A RPTP including RPTPσ, RPTPδ and
LAR (leukocyte common antigen-related phosphatase) bind
with high affinity to CSPGs and HS proteoglycans (HSPGs)
[116]. They are postulated to be the receptors of CSPG [117,
118]. RPTPσ knockout mice display a reduced CSPG inhibi-
tion after spinal cord injury and an enhanced regeneration after
sciatic nerve crush injury [112, 119]. Mimetic peptide of
RPTPσwedge domain releases CSPG-mediated axonal inhibi-
tion in vitro by binding to RPTPσ and improve the functional
recovery after SCI [120]. Binding of CSPG to RPTPσ induces
a dephosphorylation of tropomyosin-related kinase B (TrkB),
which leads to a down-regulation of dendritic spine formation
[121]. TrkB is the BDNF receptor which, in contrast to CSPG,
positively regulates the plasticity and spines formation in cor-
tical neurons. Remarkably, binding of RPTPσ to CSPGs or
HSPGs induces opposite effect on axonal growth. Cole et al.
have shown that RPTPσ binding to HSPGs activates axonal
growth while binding to CSPGs inhibits it [118]. The binding
with CS chains inhibit the oligomerization of RPTPσwhich are
induced by HSPG [118].
LAR is another CSPG receptor [122]. It has been demon-
strated by co-immunoprecipitation that LAR interacts with
CSPG directly. This interaction leads to an inactivation of Akt
and an activation of RhoA, thus inhibiting axonal growth [122].
Moreover, LAR knockout mice or mice treated with LAR-
targeting peptides show an improvement of locomotor function
after SCI [122, 123]. PG-RPTPs interaction may be a potential
therapeutic target for functional recovery after CNS injuries.
Nogo receptors NgR1 and NgR3 bind to Nogo and induce
neurite outgrowth inhibition [124]. It has recently been report-
ed that apart from Nogo, they can also bind to CSPGs and act
as CSPGs receptors [125]. Both NgR1 and NgR3 bind specif-
ically to disulfated CS-B, CS-D and CS-E with high affinity.
The binding of CSPG to NgR1 and NgR3 inhibit neurite
outgrowth. Double knockout of NgR1 and 3 shows increased
regeneration after injury, and this is further enhanced with
additional ablation of RPTPσ [125].
iii) Adhesion molecules
Cell adhesion molecules (CAMs) are surface glycoproteins
mediating cell-cell and cell-extracellular interaction. The
established connections between cells are important for main-
taining tissue integrity and for cell communications [126].
Moreover, CAMs are fundamental for cell migration, notably
during development of the CNS [127] and after traumatic
brain injury [128]. Neural-CAM (N-CAM) is an adhesion
molecule specific to the CNS. It has been implicated in vari-
ous neuronal mechanisms. Indeed, this molecule is required
for motor neuron sprouting, having thus a beneficial role in
recovery after SCI. NCAM−/− mice show a significantly re-
duced locomotor recovery comparing the WT after SCI [129,
130]. N-CAM and neuron-glia CAM (Ng-CAM) bind with
high affinity (Kd ≈ 0.5 nM) to the CSPG phosphacan [131].
Treatment with ChABC only reduces this binding by ~15%
suggesting that the binding is mostly due to an interaction with
the phosphacan core protein. The interaction of phosphacan
and N-CAM or Ng-CAM leads to an reduced neurite out-
growth and adhesion in vitro [131]. Neurocan, another
CSPG in the CNS matrix, also binds to N-CAM and Ng-
CAM, and inhibits the neurite outgrowth [132]. Unlike
phosphacan, ChABC treatment of neurocan significantly re-
duces this binding suggesting the interaction is mainly medi-
ated through the CS GAG chains [132]. These findings sug-
gest that N-CAM and Ng-CAM could be the receptors for the
two CSPGs phosphacan and neurocan.
CAMs are also involved in other neuronal mechanisms in
addit ion to neuronal migrat ion. Contactin-1 is a
glycosylphosphatidyl inositol (GPI)-linked membrane glyco-
protein. It is a CAM and implicated in axonal growth, axonal
and dendritic interactions of cerebellar interneurons and guid-
ance [133]. With the use of SPR analysis, it has been shown
that CS-E binds to contactin-1 with significant affinity
(Kd ≈ 1.4 μM) and that this interaction is required for the
neurogenesis mediated by CS-E [134].
iv) Guidance proteins
Guidance of dendrites and axons to their appropriate targets
is a critical process for building a functional CNS during de-
velopment [135]. These guidance molecules come from differ-
ent families of proteins including secreted or cell surface guid-
ance molecules and they can be attractive or repulsive [136].
Semaphorin is a large family of secreted and membrane-
associated guidance molecules [137]. Initially being identified
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as repulsive guidance molecules, several studies in the last
decades have reported a chemoattractive role of semaphorins
[138–140]. Semaphorins guide the development of peripheral
nerve projection and involved in synaptogenesis in the CNS
[141, 142]. The persistence of their expression in adulthood
suggests a role in the maintenance of pre-established connec-
tions and cerebral homeostasis [143].
Semaphorin 3A (Sema 3A) is one of the most studied
members in class III semaphorins, which are upregulated
after CNS injuries [144]. Owing to its ability in inducing
growth cone collapse, Sema 3A is also called collapsin-1
and is the first member being identified in the semaphorin
family [138]. It is a secreted protein, signaling via
neuropilin-1(Nrp-1) and plexin (Plxn) receptors located at
synapses [145–147]. During development, Sema 3A is
expressed in a gradient across the cortical layers. It acts
as a chemoattractive protein to guide the radial migration
of cortical neurons [148]. In adult CNS, Sema 3A is found
in the PNNs [78]. It modulates synapse morphology and
function [147]. ChABC digestion reduces Sema 3A stain-
ing on the PNNs, suggesting an interaction between Sema
3A and CSPG [78]. Further investigations have shown that
Sema 3A interacts with CS-E with high affinity [57].
Moreover, Nrp-1 can be modified post-translationally by
CS chains, and this modification affects its ability to one of
its effector VEGF [149]. These studies suggest that CSPGs
could be additional constituents in the Sema 3A–Nrp-Plxn
signalling complex. Moreover, Sema 3A is one of the most
potent inhibitors to neuronal sprouting after SCI. It inhibits
the axonal sprouting induced by nerve growth factor after
SCI [150]. Indeed, Sema 3A could be one of the mecha-
nisms which CSPG modulates plasticity. Targeting Sema
3A or its interaction with CSs could be a strategy to im-
prove the plasticity after CNS trauma.
Semaphorin 5A (Sema 5A) is a membrane-associated
semaphorin. Like other semaphorins, it is important in the
development of the CNS [151]. Semaphorins class 5 is char-
acterized by a specific domain containing two clusters of type-
1 thrombospondin repeats (TSRs), which promote neurite out-
growth [152]. TSR displays a basic motif which can interact
with the negative chain of HSPG and CSPG [153, 154].
Interestingly, the binding of Sema 5A to HSPG or CSPG
triggers opposite responses. Sema 5A mediates neuronal at-
traction when it binds to HSPG and it becomes repulsive upon
binding to CSPG [155]. This study indicates the proteoglycan-
dependent function of Sema 5A.
Other than Sema 3A and 5A, Conrad et al. have tried to
identify other ECM proteins which interact with CNS GAGs
to promote the growth and differentiation of embryonic sen-
sory nerve fibres using SPR and microarrays. The results in-
dicate a significant interaction between CS-A and various
guidance molecules, including Sema 3E, Sema 6B, ephrin
A3 and Robo 2 [156].
Collapsin response mediator protein-4 (CRMP-4) is a
65 kDa phosphoprotein expressed in the CNS during devel-
opment and in adulthood [157]. Dendrites extension of hip-
pocampal neurons induced by Sema 3A is impaired in
CRMP-4−/− hippocampal neurons, suggesting that CRMP-
4 belongs to the Sema 3A signalling pathway which induces
the growth cone collapse [158]. Moreover, CRMP-4 is iden-
tified as crucial protein that overcomes both axonal growth
inhibition and scarring after SCI in adult mouse [158].
Interestingly, this intracellular protein interacts with CS.
Indeed, CRMP-4 was purified using a CS affinity column
[159, 160]. During early development in the CNS, active
apoptosis which is essential for the normal development of
CNS, causes the release of CRMP-4 into the extracellular
space where it binds to CS [161, 162]. The downstream
mechanism of the interaction between CRMP-4 and CS re-
mains unknown but the above finding suggests an additional
role of CNS ECM in sequestrating intracellular protein (s)
released from apoptosis.
Orthodenticle homeobox protein 2 (Otx2) is another in-
tracellular protein found interacting with CS in the ECM.
Otx2 is a non-cell-autonomous transcription factor involved
in brain morphogenesis [163]. It has been shown to interact
with CSs in postnatal development and control plasticity
[79]. Indeed, the role of Otx2 in plasticity has been investi-
gated in the visual system in mice during the critical period.
During this period, Otx2 is transferred from choroid plexus
into the visual cortex and accumulates on the PNN of PV-
cells [164]. Otx2 accelerates PV-cells maturation and PNNs
formation. In return, PNNs concentrate Otx2 into the surface
of PV-cells to be internalized [55]. A positive feedback loop
between Otx2 and PNNs, during critical period as well as in
maintaining PNN in adulthood, has been proposed [165].
Considering the important role of Otx2 and PNNs in con-
trolling plasticity, further experiments have been performed
to characterize the binding site of Otx2 in PNNs. Isothermal
titration calorimetry (ITC) experiments show that a specific
basic sequence in Otx2, rich in arginine and lysine, interacts
specifically and with high affinity with CS-E and CS-D, low
affinity with CS-C and not with CS-A [55]. This finding
indicates, once more, that the interaction CS-protein is
sulfation pattern-dependent, not charge dependent.
v) Extracellular matrix proteins
A number of fibrillar and glyco- proteins are also key com-
ponents of the neuronal ECM in addition to CSPGs. They
consist mainly of elastins, collagens, laminins and fibronectins
[166]. Despite their small proportion in CNS matrix compar-
ing to CSPGs, these proteins impose significant influence on
the growth cone of neurons and regeneration [167, 168]. An
addition of laminin to neurons in culture results in a drastic
acceleration of neurite outgrowth [168]. Similarly, fibronectin
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promotes the neurite outgrowth and axonal regeneration of
adult brain neurons in vitro [169]. Collagen VI protects the
brain from neurodegeneration in ageing [170]. CSPGs and
fibrous proteins have a complementary functions. Both work
on the maintenance of the ECM homeostasis and the sur-
rounding neurons. An implantation of a collagen/chondroitin
6-sulfate (CS-C) hydrogel containing embryonic striatal neu-
rons allows the reconstruction of matrix and glial repair after a
lesion in rat striatum [171]. It is likely that CSPGs and fibrous
proteins interact with each other to accomplish their function.
Astrochondrin, a CSPG on astrocyte surface and is involved
in cerebellar granule cell migration, has been shown to interact
specifically with laminin and collagen but not with fibronec-
tin. Implication of CS chain of astrochondrin in this interac-
tion is demonstrated by analysis of the astrochondrin binding
to collagen in the presence of soluble CS in a radioligand
binding assay. Indeed, soluble CSs are able to compete with
astrochondrin to bind to collagen [172]. Snow et al. have
reported that laminin and fibronectin are responsible for the
inhibition effect of CSPGs on the growth cone [173].
Photomedin is another brain ECM protein, interacting
with CS, less known comparing to fibronectin and laminin
because it is less abundant and its spatiotemporal expression
is restricted [174]. Photomedin 1 and 2 are identified as
novel members of the olfactomedin family (OLF) [174].
OLFs are glycoproteins expressed mainly in the ECM of
olfactory neuroepithelium, while photomedins are expressed
mainly in retina ECM. They contain a specific sequence in
their C-terminal, called OLF domain which has crucial im-
plications in many neuronal mechanisms, including axonal
growth and differentiation of chemosensory cilia [175].
ELISA experiments have shown that photomedins bind to
CS-E with high affinity [174]. This is yet another evidence
that CS-E interacts with different growth factors involved in
neuronal migration and axonal guidance. Taken together, it
may suggest that photomedins and growth factors could
compete to bind to CS-E. Photomedins are proposed as a
reservoir of CS-E and facilitates the localized action of
growth factors [174].
vi) Pathological protein
Amyloid precursor protein (APP) is a transmembrane
glycoprotein. APP undergoes a proteolytic processes giv-
ing rise to various peptides. Some of the resulting pep-
tides are involved in neuronal plasticity and neurogenesis,
but some of the others are pathological like amyloid beta
peptide (Aβ) [176]. Indeed, Aβ is neurotoxic and found
accumulated in neurons suffering from Alzheimer’s dis-
ease [177]. HSs and CSs have been reported to enhance
the Aβ aggregation and the sulfate moieties on GAGs are
the crucial key for this aggregation [178]. Recent study
has reported that an overexpression of heparanase
decreases the amyloid burden in vivo [179], and that
PNN neurons resist neurotoxicity from Aβ and oxidative
stress suggesting the neuroprotective role of PNNs [180,
181]. Otherwise, an interaction of APP and PG enhances
the neurite outgrowth [182]. The direct interaction of
CSPGs and APP has been demonstrated using solid
phase binding assay. ChABC digestion of CS reduces
the binding by 79%, this confirms the binding is through
CS GAG chains [182].
While CSs/CSPGs are abundant in the CNS, study of
PGs/GAGs interaction has been focused on HSPGs/HSs in-
stead. Since amyloid beta peptide (Aβ) is accumulated in
the extracellular space, which is rich in CSPGs, a specific
and significant interaction could be suspected. Further inves-
tigation will shed light on the role of CSPG and CS chain in
this disease. In addition, CS has been implicated in a num-
ber of other neuropathological conditions including epilepsy,
stroke, schizophrenia, an in-depth understanding of the role
of CS in these diseases will be crucial for targeting CS in the
conditions [81, 183, 184].
Conclusion
CS is the most abundant GAG in the CNS matrix. Its diverse
pattern of sulfation and epimerization pattern allows precise
controls of various physiological processes including the
proper development of the CNS and the maintenance of neu-
ronal homeostasis. Moreover, this diversity enables differen-
tial binding to a large family of proteins, with different affin-
ities. This huge interaction between CSs and proteins places
them at the first position in diverse signalling pathways. Thus,
their involvement in various mechanisms during ontogenesis
notably the growth cone, regeneration and plasticity.
Targeting the compositional change in CS as well as their
interactions could be a promising approach to treat different
pathologies. Chemical synthesis of CS oligosaccharides with
defined sequences has recently made progresses [185, 186],
opening the possibility to use those to manipulate a protein-
CS interaction. Meanwhile, a better understanding of CS
structure, their organization within the matrix, the mode of
interaction with different types of proteins, are essential for
targeting the important ECM component in the CNS.
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